Zevra Therapeutics (ZVRA) Non-Current Assets (2016 - 2025)
Historic Non-Current Assets for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $45.0 million.
- Zevra Therapeutics' Non-Current Assets fell 5114.38% to $45.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $250.6 million, marking a year-over-year decrease of 579.76%. This contributed to the annual value of $13.4 million for FY2024, which is 2293.58% up from last year.
- Latest data reveals that Zevra Therapeutics reported Non-Current Assets of $45.0 million as of Q3 2025, which was down 5114.38% from $29.9 million recorded in Q2 2025.
- Zevra Therapeutics' 5-year Non-Current Assets high stood at $92.1 million for Q3 2024, and its period low was $2.0 million during Q3 2023.
- Over the past 5 years, Zevra Therapeutics' median Non-Current Assets value was $17.9 million (recorded in 2021), while the average stood at $27.4 million.
- As far as peak fluctuations go, Zevra Therapeutics' Non-Current Assets plummeted by 9432.15% in 2023, and later surged by 457795.84% in 2024.
- Zevra Therapeutics' Non-Current Assets (Quarter) stood at $17.9 million in 2021, then grew by 25.84% to $22.5 million in 2022, then plummeted by 51.57% to $10.9 million in 2023, then grew by 22.94% to $13.4 million in 2024, then skyrocketed by 235.83% to $45.0 million in 2025.
- Its Non-Current Assets stands at $45.0 million for Q3 2025, versus $29.9 million for Q2 2025 and $12.3 million for Q1 2025.